Valcivir

Valcivir (Valacyclovir Hydrochloride) is an antiviral medication used to treat herpes zoster (shingles), herpes simplex, herpes labialis (cold sores), genital herpes and chickenpox (varicella zoster) infections. The main ingredient in this medicine is classified as a purine nucleoside analog, and it undergoes conversion to aciclovir in the body, possibly as a result of an enzyme known as valaciclovir hydrolase. Following this, it starts to work through disruption and inhibition of viral DNA synthesis, thereby stopping the spread of the herpes virus.

Valcivir (Valacyclovir Hydrochloride) tablets are available as 2 different strength versions, including 500mg and 1000mg tablets. Immunocompetent adults treating herpes zoster infections may be directed by their physician to commence treatment as quickly as possible upon diagnosis. It is possible that they may be directed by the physician in charge of treatment to administer 1000mg, 3 times per day for a period of 7 days. Patients treating genital herpes or other conditions may be told to take it according to a different dosing schedule. In all cases, it is essential to follow the directions of the physician in charge of treatment.

If any side effects occur during treatment of herpes simplex or other conditions with Valcivir (Valacyclovir Hydrochloride) tablets, ensure that you inform your physician. Possible examples can include:

• Nausea
• Fatigue
• Sore joints
• Soreness in the throat
• Blocked or stuffy nose

Other side effects might possibly occur. Consult your physician straight away if you suffer from seizures, hallucinations, aggressive behavior, soreness in the lower back, reduction in appetite or any other severe adverse events that have not been referenced in this paragraph.

Valcivir (Valacyclovir Hydrochloride) tablets will not cure the herpes virus nor will they prevent the virus from being spread to others via sexual contact or by other means.

Patients who suffer from HIV or other immune system related disorders, kidney disease or who have undergone transplants must inform their physician of this prior to commencing treatment.